Inactive Instrument

Translate Bio, Inc.

Equities

TBIO

US89374L1044

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P TMI Index CI
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P Global BMI Index CI
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from S&P Biotechnology Select Industry Index CI
Insider Sell: Translate Bio MT
Insider Sell: Translate Bio MT
Insider Sell: Translate Bio MT
Translate Bio : Sanofi Completes Translate Bio Buyout MT
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from NASDAQ Composite Index CI
Translate Bio, Inc.(NasdaqGS:TBIO) dropped from NASDAQ Biotechnology Index CI
Sanofi completed the acquisition of remaining 95.1% stake in Translate Bio, Inc. from The Baupost Group, LLC, Ronald Renaud and other shareholders. CI
VC Daily : Laronde Fundraising Haul Reflects -2- DJ
VC Daily : Laronde Fundraising Haul Reflects Search for Next Moderna DJ
Translate Bio, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
AstraZeneca : Analysis-Sanofi's COVID-19 vaccine setback, drug pipeline cast long shadow RE
TRANSLATE BIO : Roth Capital Adjusts Translate Bio's Price Target to $38 from $45, Keeps Neutral Rating MT
Apple : S&P 500 closes at record high as Apple, healthcare stocks help shrug off Delta worries RE
Top Midday Gainers MT
TRANSLATE BIO : SVB Leerink Adjusts Translate Bio's Price Target to $38 from $19, Keeps Market Perform Rating MT
TRANSLATE BIO : Jefferies Downgrades Translate Bio to Hold from Buy MT
TRANSLATE BIO : William Blair Downgrades Translate Bio to Market Perform From Outperform MT
Global markets live: Sanofi, Alphabet, BMW, Ford, Tencent... Our Logo
GlaxoSmithKline : Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal RE
Today on Wall Street: Corporate profits rise by a level not seen since 2009 Our Logo
Sector Update: Health Care Stocks Flat To Higher Pre-Bell Tuesday MT
DJ Industrial : Wall Street Set for Small Gains, Earnings in Focus MT
Chart Translate Bio, Inc.
More charts
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell's own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.
More about the company
  1. Stock
  2. Equities
  3. Stock Translate Bio, Inc. - Nasdaq
  4. News Translate Bio, Inc.
  5. Translate Bio : Jefferies Adjusts Translate Bio's Price Target to $25 from $28, Keeps Buy Rating